The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for primary and metastatic liver tumors. It delivers SD-101, a class C toll-like receptor 9 (TLR9) agonist.
Get the full story at our sister site, Drug Delivery Business News.